A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer

DNA methyltransferase 1 (DNMT1) is scientifically validated as a molecular target to treat chemo-resistant pancreatic ductal adenocarcinoma (PDAC). Results of clinical studies of the pyrimidine nucleoside analog decitabine to target DNMT1 in PDAC have, however, disappointed. One reason is high expre...

詳細記述

保存先:
書誌詳細
出版年:Am J Cancer Res
主要な著者: Sohal, Davendra, Krishnamurthi, Smitha, Tohme, Rita, Gu, Xiaorong, Lindner, Daniel, Landowski, Terry H, Pink, John, Radivoyevitch, Tomas, Fada, Sherry, Lee, Zhenghong, Shepard, Dale, Khorana, Alok, Saunthararajah, Yogen
フォーマット: Artigo
言語:Inglês
出版事項: e-Century Publishing Corporation 2020
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7539776/
https://ncbi.nlm.nih.gov/pubmed/33042633
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料